UNSPSC 51141533: Divalproex

This classification denotes an anticonvulsant agent with the molecular formula 2C8H15O2.H+.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 644VL95AO6, chemically known as pentanoic acid, 2-propyl-, sodium salt (2:1) but generally known as divalproex sodium, which bears US NIH Compound Identifier 53519. European Medicines Agency schedules Divalproex sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20309.

The term VALPROATE SEMISODIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). SMILES: CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[NA+].

UNSPSC 51141533 Divalproex, a Commodity code, nominally addresses a specific anticonvulsant medication, but recent state and local procurement activity under this code reflects a broader pharmaceutical and health supply acquisition pattern. The solicitations posted show state and local governments buying naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals through competitive bidding and cooperative purchasing mechanisms. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate purchasing cooperatives (Minnesota Multistate Cooperative Purchasing Alliance). Procurement approaches range from straightforward IFBs for specific quantities of finished goods to RFIs for market intelligence on direct-to-manufacturer prescription distribution models and RFPs for framework agreements covering multiple pharmaceutical products distributed through authorized wholesalers.

Recent activity concentrates in Florida, Texas, and Minnesota. The most current opportunity is Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, a two-year initial term with one-year renewal option, and potential FEMA funding. Texas HHS issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription fulfillment outside traditional PBM and GPO channels. Minnesota's MMCAP, administered through the Department of Administration's Office of State Procurement, released RFP S1070000015802 (posted January 20, 2026, proposals due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and awards effective July 1, 2026. Vendors in all three solicitations must comply with cGMP and drug-supply-chain security requirements, maintain specified insurance coverage, and submit pricing in standardized formats compatible with state e-procurement systems.